CPT® Code 90624

Official Description

Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use

Common Language Description

The CPT® Code 90624 refers to a specific meningococcal pentavalent vaccine designed to provide active, long-term immunity against meningococcal disease. This vaccine works by exposing the recipient's immune system to altered versions of the pathogens responsible for the disease, prompting the immune system to produce its own antibodies. The body retains a memory of how to generate these antibodies, allowing for a quicker and more effective response upon subsequent exposures to the antigens. Meningococcal disease, while rare, poses a significant health risk as it can lead to severe infections affecting the brain, spinal cord, and bloodstream. The disease can progress rapidly, often within 24 hours, and is particularly prevalent among teenagers and young adults. The vaccine itself comprises two sterile components: the pentavalent MenACWY vaccine, which includes equal amounts of polysaccharides conjugated to a diphtheria toxoid carrier to enhance the immune response, and the MenB-4C component, which typically contains multiple recombinant proteins such as neisserial adhesin A (NadA), factor H binding protein (FHbp), and neisserial heparin binding antigen (NhbA), along with outer membrane vesicles derived from serogroup B meningococcal bacteria. It is important to note that this code specifically reports the vaccine product used and does not encompass the administration of the vaccine itself.

1. Indications

The meningococcal pentavalent vaccine, represented by CPT® Code 90624, is indicated for the prevention of meningococcal disease caused by serogroups A, C, W, Y, and B. This vaccine is particularly recommended for individuals at increased risk of meningococcal infections, including:

Teens and Young Adults: This demographic is at a higher risk for meningococcal disease, making vaccination crucial for their protection.
Individuals with Certain Medical Conditions: Those with specific health conditions that compromise their immune system or increase susceptibility to infections may require this vaccine.
Travelers to Endemic Areas: Individuals traveling to regions where meningococcal disease is prevalent should receive this vaccine to reduce their risk of infection.

2. Procedure

The administration of the meningococcal pentavalent vaccine involves several key procedural steps, which are outlined as follows:

Step 1: Preparation of the Vaccine The vaccine must be prepared according to the manufacturer's guidelines. This includes ensuring that the vaccine is stored at the appropriate temperature and is not expired. The healthcare provider should inspect the vaccine for any particulate matter or discoloration before use.
Step 2: Patient Assessment Prior to administration, the healthcare provider should assess the patient’s medical history, including any previous allergic reactions to vaccines, current medications, and overall health status to ensure that the patient is a suitable candidate for the vaccine.
Step 3: Administration of the Vaccine The vaccine is administered intramuscularly, typically in the deltoid muscle of the upper arm for adults and older children, or in the anterolateral thigh for infants and young children. The provider should use a sterile needle and syringe, and follow proper aseptic techniques to minimize the risk of infection.
Step 4: Post-Administration Monitoring After the vaccine is administered, the patient should be monitored for a short period to observe for any immediate adverse reactions. This is particularly important for individuals who may have a history of allergic reactions to vaccines.

3. Post-Procedure

Following the administration of the meningococcal pentavalent vaccine, patients may experience mild side effects, which can include soreness at the injection site, low-grade fever, or fatigue. These effects are generally short-lived and resolve without intervention. Patients should be advised to rest and hydrate adequately. It is also important to inform patients about the signs of a severe allergic reaction, such as difficulty breathing, swelling of the face or throat, or a rapid heartbeat, and instruct them to seek immediate medical attention if these symptoms occur. Additionally, patients should be encouraged to keep a record of their vaccination status for future reference and to ensure they receive any necessary booster doses as recommended by healthcare guidelines.

Short Descr	MENB-4C&MENACWY VACC IM
Medium Descr	MENIGCCAL PNTVLNT MENB-4C & MENACWY VACC IM USE
Long Descr	Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Non-Covered Service, not paid under OPPS
Type of Service (TOS)	1 - Medical Care
Berenson-Eggers TOS (BETOS)	none
MUE	1